<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606240</url>
  </required_header>
  <id_info>
    <org_study_id>PSL-AC-11-11-15</org_study_id>
    <nct_id>NCT02606240</nct_id>
  </id_info>
  <brief_title>Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG</brief_title>
  <official_title>Extracorporeal CO2 Removal (ECCO2R) With a Renal Replacement Platform (PRISMALUNG) to Enhance Lung Protective Ventilation in Patients With Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot observational study will assess changes in pH /PaO2 /PaCO2, Respiratory Rate and
      device CO2 clearance in the first 24 hours of Extracorporeal CO2 removal (ECCO2R) following
      tidal volume (Vt), and plateau pressure reduction in patients with mild to moderate ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extracorporeal CO2 removal (ECCO2R) with a low-flow CO2 removal device (Prismalung,
      Gambro-Baxter) integrated on the Prismaflex platform (Gambro-Baxter) allows tidal volume (Vt)
      and plateau pressure reduction in patients with mild to moderate ARDS. This pilot
      observational study will assess changes in pH /PaO2 /PaCO2, Respiratory Rate and device CO2
      clearance in the first 24 hours of ECCO2R following Vt and plateau pressure reduction in
      patients with mild to moderate ARDS. Safety variables during treatment will also be analyzed.
      A series of 20 consecutive patients will be included in this observational study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who achieved a tidal volume (Vt) reduction to 4 mL/kg while maintaining pH and PaCO2 to ± 20% of baseline values obtained at Vt of 6 mL/kg.</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of participants who achieved a tidal volume (Vt) reduction to 4 mL/kg while maintaining pH and PaCO2 to ± 20% of baseline values obtained at Vt of 6 mL/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in Vt</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of changes in Vt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in Plateau Pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of changes in Plateau Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in respiratory rate</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of changes in respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in Positive End-Expiratory Pressure, PEEP</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of changes in Positive End-Expiratory Pressure, PEEP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vasopressor use</measure>
    <time_frame>24 hours</time_frame>
    <description>Epineprine and norepinephine dose, mcg/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of lung recruitment/derecruitment</measure>
    <time_frame>24 hours</time_frame>
    <description>With lung echography. Ccording to the method described by Bouhemad et al, Am J Respir Crit Care Med. 2011 Feb 1;183(3):341-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lifetime of the extracorporeal circulation</measure>
    <time_frame>7 days</time_frame>
    <description>In hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events directly related to ECCO2R</measure>
    <time_frame>7 days</time_frame>
    <description>Adverse events directly related to ECCO2R are hemolysis (serum free hemoglobin &gt;500 mg/L), infection at the cannulation site, Hemorrhage at the cannulation site, air entry in the circuit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Mild to Moderate ARDS on PRISMALUNG</arm_group_label>
    <description>Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 removal with PRISMALUNG in ARDS</intervention_name>
    <description>Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.</description>
    <arm_group_label>Mild to Moderate ARDS on PRISMALUNG</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Mild to Moderate ARDS according to the Berlin definition of ARDS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mechanical ventilation with expected duration of &gt;24 hours

          -  Mild to moderate Acute Respiratory Distress Syndrome (ARDS) according to the Berlin
             definition: 100 mmHg &lt;PaO2/FiO2 &lt;300 mmHg, with PEEP &gt; 5 cmH2O

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy

          -  Severe hypoxemia with PaO2/FiO2 &lt;100 mmHg

          -  Body mass index &gt; 40 kg/m2

          -  Decompensated heart insufficiency or acute coronary syndrome

          -  Severe Chronic obstructive pulmonary disease (COPD)

          -  Major respiratory acidosis with PaCO2 &gt;60 mmHg

          -  Acute brain injury

          -  Severe liver insufficiency (Child-Pugh scores &gt;7) or fulminant hepatic failure

          -  Heparin-induced thrombocytopenia

          -  Contraindication for systemic anticoagulation

          -  Patient moribund, decision to limit therapeutic interventions

          -  Catheter access to femoral vein or jugular vein impossible

          -  Pneumothorax

          -  Platelet &lt;50 G/L

          -  Lacking consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU AMIENS, Département Anesthésie Réanimation</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon, Réanimation</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CLERMONT FERRAND, Département Anesthésie Réanimation</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU MONTPELLIER, Département Anesthésie Réanimation</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié Salpetriere, Reanimation Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>August 5, 2017</last_update_submitted>
  <last_update_submitted_qc>August 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Alain COMBES</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

